RT @RyanCaputo1: This may be my biggest pet peeve: “Defer MRA to outpatient start” It’s recommended to check K at 3-7 days post initiatio…
RT @RyanCaputo1: This may be my biggest pet peeve: “Defer MRA to outpatient start” It’s recommended to check K at 3-7 days post initiatio…
RT @RyanCaputo1: This may be my biggest pet peeve: “Defer MRA to outpatient start” It’s recommended to check K at 3-7 days post initiatio…
This may be my biggest pet peeve: “Defer MRA to outpatient start” It’s recommended to check K at 3-7 days post initiation, then monthly x3 months. Start in 🏥 and get the 3 day K check. What are the odds this gets initiated out patient? See figure 1. ht
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @JavedButler1: It took us some time to get this done but this JACC feature of central illustration does force one to summarize succinctl…
RT @JavedButler1: It took us some time to get this done but this JACC feature of central illustration does force one to summarize succinctl…
It took us some time to get this done but this JACC feature of central illustration does force one to summarize succinctly and precisely.
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
So important to address this in every heart failure visit inpatient or outpatient!
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Thanks @hvanspall. Two more below. Targeted performance improvement interventions have been shown to reduce site variation and…
Thanks @hvanspall. Two more below. Targeted performance improvement interventions have been shown to reduce site variation and improve use of GDMT. More focused efforts to improve dosing are needed. https://t.co/ypt6P0iWCh https://t.co/obHiSkX7Sk
RT @JACCJournals: How well do we treat #heartfailure patients with optimal doses of GDMT? Find out in the newest issue of #JACC. https://t.…
Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction https://t.co/Dxzf5MqA4p
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @ATRIUMRx: Unfortunately, new data from CHAMP-HF show that most eligible HFrEF patients did not receive target doses of medical therapy…
RT @JACCJournals: #JACC study finds the majority of eligible #heartfailure patients in the US never receive target doses of GDMT at any poi…
RT @rcstarling: Thanks for your leadership Gregg. @HFSA is fully supportive and this is an opportunity for HFSA. We accept the challenge!@r…
Very proud of my team for uptitrating GDMT on oncology rounds this morning. Always have to keep this in mind! @NU_IntMed
RT @JACCJournals: How well do we treat #heartfailure patients with optimal doses of GDMT? Find out in the newest issue of #JACC. https://t.…
RT @JACCJournals: #JACC study finds the majority of eligible #heartfailure patients in the US never receive target doses of GDMT at any poi…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @JACCJournals: #JACC study finds the majority of eligible #heartfailure patients in the US never receive target doses of GDMT at any poi…
RT @JACCJournals: #JACC study finds the majority of eligible #heartfailure patients in the US never receive target doses of GDMT at any poi…
RT @JACCJournals: #JACC study finds the majority of eligible #heartfailure patients in the US never receive target doses of GDMT at any poi…
RT @JACCJournals: #JACC study finds the majority of eligible #heartfailure patients in the US never receive target doses of GDMT at any poi…
RT @NLAltmanMD: Not infrequently I am referred patients "not tolerating" medical therapy, but with slow titration we get them out of acute…
RT @JACCJournals: #JACC study finds the majority of eligible #heartfailure patients in the US never receive target doses of GDMT at any poi…
RT @JACCJournals: #JACC study finds the majority of eligible #heartfailure patients in the US never receive target doses of GDMT at any poi…
Not infrequently I am referred patients "not tolerating" medical therapy, but with slow titration we get them out of acute HF, improve EF and avoid VAD/transplant... education is key!!
RT @ernestocardio: Titration of Medical Therapy for Heart Failure With Reduced Ejection F... https://t.co/d2q3vTKCbB @mencardio @drjarayg @…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
Great study, critical findings. And getting GDMT right saves lives and can dramatically improve symptoms. Advance until max dose or symptoms
RT @JACCJournals: #JACC study finds the majority of eligible #heartfailure patients in the US never receive target doses of GDMT at any poi…
RT @JACCJournals: #JACC study finds the majority of eligible #heartfailure patients in the US never receive target doses of GDMT at any poi…
RT @JACCJournals: #JACC study finds the majority of eligible #heartfailure patients in the US never receive target doses of GDMT at any poi…
RT @JACCJournals: #JACC study finds the majority of eligible #heartfailure patients in the US never receive target doses of GDMT at any poi…
RT @JACCJournals: #JACC study finds the majority of eligible #heartfailure patients in the US never receive target doses of GDMT at any poi…
RT @JACCJournals: #JACC study finds the majority of eligible #heartfailure patients in the US never receive target doses of GDMT at any poi…
#JACC study finds the majority of eligible #heartfailure patients in the US never receive target doses of GDMT at any point in routine follow-up. How can we improve? https://t.co/vhwrQqjOD3 https://t.co/maCJoiGnE6
Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction https://t.co/Dxzf5MqA4p
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @jsenior64: Iniciación y titulación de medicamentos en falla cardiaca, oportunidades de mejorar prescripción, titulación y adherencia. N…
RT @JACCJournals: How well do we treat #heartfailure patients with optimal doses of GDMT? Find out in the newest issue of #JACC. https://t.…
RT @JACCJournals: How well do we treat #heartfailure patients with optimal doses of GDMT? Find out in the newest issue of #JACC. https://t.…
RT @JACCJournals: How well do we treat #heartfailure patients with optimal doses of GDMT? Find out in the newest issue of #JACC. https://t.…
RT @JACCJournals: How well do we treat #heartfailure patients with optimal doses of GDMT? Find out in the newest issue of #JACC. https://t.…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction | JACC: Journal of the American College of Cardiology https://t.co/1vStmXUBDg
RT @JACCJournals: How well do we treat #heartfailure patients with optimal doses of GDMT? Find out in the newest issue of #JACC. https://t.…
RT @JACCJournals: How well do we treat #heartfailure patients with optimal doses of GDMT? Find out in the newest issue of #JACC. https://t.…
RT @JACCJournals: How well do we treat #heartfailure patients with optimal doses of GDMT? Find out in the newest issue of #JACC. https://t.…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
Starting GDMT is not enough. Titrate, titrate, titrate.
RT @JACCJournals: How well do we treat #heartfailure patients with optimal doses of GDMT? Find out in the newest issue of #JACC. https://t.…
RT @JACCJournals: How well do we treat #heartfailure patients with optimal doses of GDMT? Find out in the newest issue of #JACC. https://t.…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @JACCJournals: How well do we treat #heartfailure patients with optimal doses of GDMT? Find out in the newest issue of #JACC. https://t.…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Substantial opportunity to improve patient-centered, high value HF care and outcomes in all settings. The Time is Now. #CHAMP-HF…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Substantial opportunity to improve patient-centered, high value HF care and outcomes in all settings. The Time is Now. #CHAMP-HF…
RT @gcfmd: Every patient, every visit, every clinician should be considering if the HF patient is receiving each GDMT at the optimal dose,…
RT @gcfmd: Substantial opportunity to improve patient-centered, high value HF care and outcomes in all settings. The Time is Now. #CHAMP-HF…
RT @JACCJournals: How well do we treat #heartfailure patients with optimal doses of GDMT? Find out in the newest issue of #JACC. https://t.…
RT @gcfmd: Substantial opportunity to improve patient-centered, high value HF care and outcomes in all settings. The Time is Now. #CHAMP-HF…